Literature DB >> 19372875

HIV protease resistance and viral fitness.

Monique Nijhuis1, Noortje M van Maarseveen, Charles A B Boucher.   

Abstract

PURPOSE OF REVIEW: This review focuses on the evolution of protease inhibitor resistance and replication capacity in the presence and absence of protease inhibitor pressure. RECENT
FINDINGS: Classically, HIV escapes through mutations in the protease itself causing a decrease in affinity to the inhibitor, leading to resistance. These changes also affect the binding of the enzyme to the natural substrate, and as a consequence cause a decrease in replication capacity of the virus. Continuous replication of these viruses may result in the acquisition of compensatory changes, which will fixate the drug-resistant variant in the viral population. Furthermore, novel treatment strategies have been developed to combat the development of classic protease inhibitor resistance. Using these strategies, the development of resistance in the viral protease is blocked because single or double mutations do not confer significant resistance. Alternative protease inhibitor resistance pathways are described, which enable the virus to escape these novel strategies.
SUMMARY: Suboptimal protease inhibitor pressure clearly results in the selection of mutations conferring resistance and in the acquisition of mutations compensating the initial reduction in viral replicative capacity. The major implications of the selection of these compensatory changes on evolution in the absence of protease inhibitor pressure are discussed.

Entities:  

Year:  2007        PMID: 19372875     DOI: 10.1097/COH.0b013e32801682f6

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  8 in total

1.  Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.

Authors:  Ying-Chuan Lin; Bruce E Torbett; John H Elder
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

2.  A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culture.

Authors:  Yi Liu; Sarah Holte; Ushnal Rao; Jan McClure; Philip Konopa; J Victor Swain; Erinn Lanxon-Cookson; Moon Kim; Lennie Chen; James I Mullins
Journal:  J Virol Methods       Date:  2012-11-29       Impact factor: 2.014

3.  Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.

Authors:  Ying-Chuan Lin; Meaghan Happer; John H Elder
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

4.  Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

Authors:  Karolin Meixenberger; Kaveh Pouran Yousef; Maureen Rebecca Smith; Sybille Somogyi; Stefan Fiedler; Barbara Bartmeyer; Osamah Hamouda; Norbert Bannert; Max von Kleist; Claudia Kücherer
Journal:  Virol J       Date:  2017-11-14       Impact factor: 4.099

5.  Effect of HIV/HCV Co-Infection on the Protease Evolution of HIV-1B: A Pilot Study in a Pediatric Population.

Authors:  Sara Domínguez-Rodríguez; Patricia Rojas; Carolina Fernández McPhee; Israel Pagán; María Luisa Navarro; José Tomás Ramos; África Holguín
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

Review 6.  HIV Protease: Historical Perspective and Current Research.

Authors:  Irene T Weber; Yuan-Fang Wang; Robert W Harrison
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

7.  A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Authors:  Mariam O Fofana; Sourya Shrestha; Gwenan M Knight; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence.

Authors:  Claudia Alteri; Lavinia Fabeni; Rossana Scutari; Giulia Berno; Domenico Di Carlo; Caterina Gori; Ada Bertoli; Alessandra Vergori; Ilaria Mastrorosa; Rita Bellagamba; Cristina Mussini; Manuela Colafigli; Francesco Montella; Alfredo Pennica; Claudio Maria Mastroianni; Enrico Girardi; Massimo Andreoni; Andrea Antinori; Valentina Svicher; Francesca Ceccherini-Silberstein; Carlo Federico Perno; Maria Mercedes Santoro
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.